116 related articles for article (PubMed ID: 15867391)
1. Elucidation of thioredoxin as a molecular target for antitumor quinols.
Bradshaw TD; Matthews CS; Cookson J; Chew EH; Shah M; Bailey K; Monks A; Harris E; Westwell AD; Wells G; Laughton CA; Stevens MF
Cancer Res; 2005 May; 65(9):3911-9. PubMed ID: 15867391
[TBL] [Abstract][Full Text] [Related]
2. Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets.
Chew EH; Matthews CS; Zhang J; McCarroll AJ; Hagen T; Stevens MF; Westwell AD; Bradshaw TD
Biochem Biophys Res Commun; 2006 Jul; 346(1):242-51. PubMed ID: 16756956
[TBL] [Abstract][Full Text] [Related]
3. Quinols as novel therapeutic agents. 2.(1) 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and related agents as potent and selective antitumor agents.
Berry JM; Bradshaw TD; Fichtner I; Ren R; Schwalbe CH; Wells G; Chew EH; Stevens MF; Westwell AD
J Med Chem; 2005 Jan; 48(2):639-44. PubMed ID: 15658878
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin reductase inhibition by antitumor quinols: a quinol pharmacophore effect correlating to antiproliferative activity.
Chew EH; Lu J; Bradshaw TD; Holmgren A
FASEB J; 2008 Jun; 22(6):2072-83. PubMed ID: 18180330
[TBL] [Abstract][Full Text] [Related]
5. 4-Substituted 4-hydroxycyclohexa-2,5-dien-1-ones with selective activities against colon and renal cancer cell lines.
Wells G; Berry JM; Bradshaw TD; Burger AM; Seaton A; Wang B; Westwell AD; Stevens MF
J Med Chem; 2003 Feb; 46(4):532-41. PubMed ID: 12570375
[TBL] [Abstract][Full Text] [Related]
6. Antitumor quinol PMX464 is a cytocidal anti-trypanosomal inhibitor targeting trypanothione metabolism.
König J; Wyllie S; Wells G; Stevens MF; Wyatt PG; Fairlamb AH
J Biol Chem; 2011 Mar; 286(10):8523-8533. PubMed ID: 21212280
[TBL] [Abstract][Full Text] [Related]
7. Antitumour properties of fluorinated benzothiazole-substituted hydroxycyclohexa-2,5-dienones ('quinols').
Lion CJ; Matthews CS; Wells G; Bradshaw TD; Stevens MF; Westwell AD
Bioorg Med Chem Lett; 2006 Oct; 16(19):5005-8. PubMed ID: 16908135
[TBL] [Abstract][Full Text] [Related]
8. Antitumour benzothiazoles. Part 10: the synthesis and antitumour activity of benzothiazole substituted quinol derivatives.
Wells G; Bradshaw TD; Diana P; Seaton A; Shi DF; Westwell AD; Stevens MF
Bioorg Med Chem Lett; 2000 Mar; 10(5):513-5. PubMed ID: 10743960
[TBL] [Abstract][Full Text] [Related]
9. Quinols as novel therapeutic agents. 7.1 Synthesis of antitumor 4-[1-(arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira reactions.
McCarroll AJ; Bradshaw TD; Westwell AD; Matthews CS; Stevens MF
J Med Chem; 2007 Apr; 50(7):1707-10. PubMed ID: 17343370
[TBL] [Abstract][Full Text] [Related]
10. 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro anti-tumour activity.
Bradshaw TD; Wrigley S; Shi DF; Schultz RJ; Paull KD; Stevens MF
Br J Cancer; 1998 Mar; 77(5):745-52. PubMed ID: 9514053
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxic and antiangiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: an in vitro study.
Mukherjee A; Westwell AD; Bradshaw TD; Stevens MF; Carmichael J; Martin SG
Br J Cancer; 2005 Jan; 92(2):350-8. PubMed ID: 15655539
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of antitumour (1H-1,2,3-triazol-4-yl)-4-hydroxycyclohexa-2,5-dien-1-ones by copper-catalysed Huisgen cycloadditions.
McCarroll AJ; Matthews CS; Wells G; Bradshaw TD; Stevens MF
Org Biomol Chem; 2010 May; 8(9):2078-84. PubMed ID: 20401384
[TBL] [Abstract][Full Text] [Related]
13. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
[TBL] [Abstract][Full Text] [Related]
14. Dual pharmacological inhibition of glutathione and thioredoxin systems synergizes to kill colorectal carcinoma stem cells.
Tanaka G; Inoue K; Shimizu T; Akimoto K; Kubota K
Cancer Med; 2016 Sep; 5(9):2544-57. PubMed ID: 27485632
[TBL] [Abstract][Full Text] [Related]
15. Redox active disulfides: the thioredoxin system as a drug target.
Kirkpatrick DL; Ehrmantraut G; Stettner S; Kunkel M; Powis G
Oncol Res; 1997; 9(6-7):351-6. PubMed ID: 9406241
[TBL] [Abstract][Full Text] [Related]
16. A cellular and molecular investigation of the action of PMX464, a putative thioredoxin inhibitor, in normal and colorectal cancer cell lines.
Mukherjee A; Huber K; Evans H; Lakhani N; Martin S
Br J Pharmacol; 2007 Aug; 151(8):1167-75. PubMed ID: 17572693
[TBL] [Abstract][Full Text] [Related]
17. Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents.
Engman L; Cotgreave I; Angulo M; Taylor CW; Paine-Murrieta GD; Powis G
Anticancer Res; 1997; 17(6D):4599-605. PubMed ID: 9494575
[TBL] [Abstract][Full Text] [Related]
18. 6-Shogaol inhibits breast and colon cancer cell proliferation through activation of peroxisomal proliferator activated receptor γ (PPARγ).
Tan BS; Kang O; Mai CW; Tiong KH; Khoo AS; Pichika MR; Bradshaw TD; Leong CO
Cancer Lett; 2013 Aug; 336(1):127-39. PubMed ID: 23612072
[TBL] [Abstract][Full Text] [Related]
19. Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.
Kashiyama E; Hutchinson I; Chua MS; Stinson SF; Phillips LR; Kaur G; Sausville EA; Bradshaw TD; Westwell AD; Stevens MF
J Med Chem; 1999 Oct; 42(20):4172-84. PubMed ID: 10514287
[TBL] [Abstract][Full Text] [Related]
20. New inhibitors of the thioredoxin-thioredoxin reductase system based on a naphthoquinone spiroketal natural product lead.
Wipf P; Hopkins TD; Jung JK; Rodriguez S; Birmingham A; Southwick EC; Lazo JS; Powis G
Bioorg Med Chem Lett; 2001 Oct; 11(19):2637-41. PubMed ID: 11551767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
